This chromosomal health condition causes amenorrhea and is characterized by signs and symptoms such as a low hairline, webbed ...

Challenges and Opportunities,” published in the August 2024 issue of Endocrinology by Kotwal et al. This narrative review ...

THRIVE met the primary and all secondary endpoints at 15 weeks after five infusions of veligrotug. Viridian anticipates submitting an FDA marketing application for veligrotug for thyroid eye ...

Levothyroxine treatment was associated with a reduced risk for major adverse cardiovascular events among patients with subclinical hypothyroidism.

Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other ...

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

KEY POINTS A 65-year-old woman presented to the emergency department with an 8-day history of progressive leg weakness and ...

Topline data were announced from a phase 3 study evaluating veligrotug in patients with active thyroid eye disease ... of veligrotug or placebo. The primary endpoint was proptosis responder ...

for active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and tissue damage around and behind the eyes. THRIVE met the primary and all secondary ...

Standardized incidence ratios elevated for all nonkeratinocyte skin cancers, melanoma. HealthDay News — Patients with primary thyroid cancer who receive radioactive iodine therapy have an ...